Member Info for neilrich3

I don't class Co-prep as an instrument, it can't measure....it is a device for sample handling. Also, more thank likely manufactured by a third party.

I feel that the instrument is more likely to be evolution of the Q instrument.

Hope we all took note of the following points within Vito's profile:
• Leading the software development for new instrumentation, tailoring it over the clinical data and customer needs.
• Daily reporting about meeting with customers, potential sales opportunities and issues encountered.

Specifically the software development for new instrumentation!!

Larry, Check Vito's profile:
https://www.linkedin.com/in/vito-cinquepalmi-4726695a/

Has Italy below his name.

Finally, some evidence of a European based field team, this chap is now based within Italy, before November he was UK based.
Wonder whether this was David hitting the ground running, immediately redeploying parts of the team into Europe, some of the 50 that were part of the UK based team.
Field Application Specialist - EuropeField Application Specialist - Europe
Nov 2021 - Present · 3 mosNov 2021 - Present · 3 mos
Europe
• Supporting end-user through adoption and Validation of new products.
• Looking after our European based customers
• Performing installation of new equipment on site, followed by extensive 1-to-1 training with the laboratory personnel.
• Leading the software development for new instrumentation, tailoring it over the clinical data and customer needs.
• Assisting customers with any technical query, exploring and suggesting possible applications of the products from commercial catalogue.
• Daily reporting about meeting with customers, potential sales opportunities and issues encountered.
• Planning and coordinating field visits directly with customers.

Novacyt's latest post upon Linkedin reference the trade show in Dubai has been liked by Hannah Oakley, CK Group Principal Recruitment Consultant US Division, she's based in Boston, Massachusetts. Clearly things are now happing in the USA.

Why only £70m cash for FY when the figure for H1 was £77.2m?

Someone further down this board posted an article earlier, out of Israel, highlighting doubts about the effectiveness of a fourth booster against Omicron.

Would appear that Israel might be turning its back upon the Vaccines in favour of mass testing. https://www.timesofisrael.com/mass-distribution-of-free-rapid-covid-tests-to-begin-next-week/

>64,000 new COVID cases Today for a nation with a population of <10million and a Country which has been leading the world for rate of vaccination..

This time last year COVID stocks were being hit with the roll out of the vaccines, which was a game changer apparently, however would appear that the markets got it wrong!

Wilson, My response from the DHSC below, it would appear that many companies have had to resubmit having failed to submit all the correct appropriate info in the first place.
.....Also, if the application data was submitted not according to our technical guidance ( https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/covid-19-test-approval-step-2-process-for-desktop-review ), as you see in the guidelines, we have to stop the process and go back to suppliers giving them 20 working days to provide the information – so that is an additional time frame that needs to be taken into consideration.

Also, upon page 32 they quote the Clinical Sensitivity which Private Eye's one expert suggested was missing.

Interesting that the DHSC submission document is dated 31 Dec 2021 (issue 5), clearly there has been a number of amendments, however does not equate to wrong doing, just that the document has been updated as more information has become available.

https://www.genesig.com/products/10061-genesig-covid-19-3g

Still available to purchase, therefore the current management continue to have faith in the product.....which is good enough for me!!

This all happened back in the Summer, should NCYT have had any concern with regards to the processes for validation of the 3 gene test at any point, they'd have pulled the product from sale and they'd not have submitted it to the DHSC for CTDA approval.

Mistakes have almost certainly been made along the way, as with any company, however hopefully the company has become stronger because of it, clearly David didn't rate Ajan, who's already been shown the door.

Storm in a teacup and clearly the company is giving it the attention that it deserves!!

Bedfordshire based job vacancy for Sales Manager - Distribution Sales Central and Eastern Europe
https://www.linkedin.com/jobs/search/?currentJobId=2885833133&f_C=10894668&geoId=92000000
Clearly so much going on behind the scenes.

Also, despite the UK lifting the testing requirement for travel, PCR is still required for entry into many destinations.
https://www.linkedin.com/feed/update/urn:li:activity:6886268054179860480/

You'd think that we be able to beat the £54m revenue from H1, especially when you consider that it was H2 where the aviation industry opened up and all the testing that went with that, plus the impact of Omicron from the end of November.

Have to wonder how many of that team of 50 remain? Via Linkedin I know of a number of Territory Managers that have since moved on, plus the fact that we are now recruiting Account Managers within a number of regions.

As of the 26 Nov 2021 we know that the board was more than comfortable with the full year revenue guidance and that was before the impact of Omicron, for all we know December 2021 could have been a record breaking month. 2021 Revenue is already in the bag, lets hope for a little over the previous guidance. As many have already said, the 2022 guidance is more important and David's vision for where he shall take the company, in my opinion he's unlikely to disappoint.

On 2 November 2021, Novacyt also stated that if no further products were added to the CTDA register, the impact on full year revenues for 2021 would be circa £3 million. With this approval, the financial impact on 2021 will be significantly lower as the genesig® COVID-19 test accounts for approximately 30% of the circa £3 million revenue shortfall.

Mr Big, Your wish list of updates shall more than likely be delivered next week. Are you expecting DA to bring the announcements forward by a week, just because Boris and Co. have lost the plot and the share price has taken another tumble?

Thanks Wilson.
San Antonio, officially the City of San Antonio, is the seventh-most populous city in the United States

Check the vacancies at present, you don't employ Regional Account Managers unless you have products to sell, have a feeling that the transition away from COVID testing is already well underway and I expect to hear all about it next week.